Title:
CD79B HUMANIZED ANTIBODY-BASED CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/236796
Kind Code:
A1
Abstract:
Provided are a CD79b humanized antibody-based chimeric antigen receptor and use thereof. The present disclosure relates to a CD79b humanized antibody -based chimeric antigen receptor, which includes an antigen binding domain, a transmembrane domain, a co-stimulatory signaling domain, a CD3q signaling domain, and a self-destructing domain, which are sequentially connected in tandem, wherein the antigen binding domain binds to a tumor surface antigen CD79b and is a humanized scFv targeting the tumor surface antigen CD79b, and the self-destructing domain is a cysteine protease 9 domain. When the chimeric antigen receptor is applied to patients with tumors expressing the tumor-specific target CD79b, few clinical side effects are generated, the safety is high, tumor cells can be effectively killed, and the presence of CAR-T in the patients can be monitored for a long time, effectively prolonging the overall survival rate of patients.
Inventors:
CHANG LUNG-JI (CN)
Application Number:
PCT/CN2023/096720
Publication Date:
December 14, 2023
Filing Date:
May 29, 2023
Export Citation:
Assignee:
BEIJING MEIKANG GENO IMMUNE BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K19/00; A61K39/00; A61P35/00; C12N5/10; C12N7/01; C12N15/62; C12N15/867
Foreign References:
| CN114591444A | 2022-06-07 | |||
| CN109265565A | 2019-01-25 | |||
| CN104540526A | 2015-04-22 | |||
| CN107108739A | 2017-08-29 | |||
| CN107312097A | 2017-11-03 |
Attorney, Agent or Firm:
BEYOND ATTORNEYS AT LAW (CN)
Download PDF: